Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track RAPP with free AI briefings, catalyst countdowns, and dilution alerts.

RAPP · Rapport Therapeutics, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$395M Cash on Hand
28.5mo Cash Runway
Follow RAPP by email Get an email when RAPP reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about RAPP, unsubscribe in one click. Privacy

📣 What RAPP Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
RAP-219 Focal Seizure Phase 3 · NCT07563881 Recruiting

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

RAPP holds $395M in cash and short-term investments (as of Sep 30, 2026) and burns about $41.5M/quarter from operations, an estimated runway of 28.5 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 7 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when RAPP files for a raise →

👥 Who Owns RAPP

Insiders 22.7% Institutions (227 holders) 77.3% Public and other holders 0%
HolderTypeShares% of sharesAs of
Third Rock Ventures V, L.P.
Director, 10% owner
Insider 8,678,314 14.64% 2026-10-30
Capital International Investors Institution (13G, 5%+) 2,921,958 4.93% 2026-06-30
James Healy
Director · +15,200 options
Insider 2,873,888 4.85% 2026-10-28
Cormorant Asset Management, LP Institution (13G, 5%+) 2,657,521 4.48% 2026-06-30
BlackRock, Inc. Institution (13G, 5%+) 2,397,549 4.04% 2025-12-31
Steven M Paul
Director · +15,200 options
Insider 555,022 0.94% 2026-10-22
Abraham Ceesay
Chief Executive Officer, Director
Insider 552,493 0.93% 2026-10-21
David Bredt
Chief Scientific Officer · +88,080 options
Insider 393,075 0.66% 2026-02-17
Krishnaswamy Yeleswaram
Chief Development Officer
Insider 195,862 0.33% 2026-08-24
Cheryl Gault
Chief Operating Officer
Insider 139,914 0.24% 2026-09-30
Troy A. Ignelzi
Chief Financial Officer
Insider 15,500 0.03% 2026-10-21
Wendy B. Young
Director · +15,200 options
Insider 13,289 0.02% 2026-10-22

Share count 59,279,630 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full RAPP picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for RAPP and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.